| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Uridine phosphorylase (Substrate)
|
|---|---|
| ln Vitro |
Ribose-1-phosphate serves as a substrate for uridine phosphorylase, which catalyzes the synthesis of nucleosides from 5-fluorouracil (FUra). This enzymatic reaction produces fluorouridine, the active metabolite that incorporates into RNA and inhibits thymidylate synthase in cancer cells.
|
| ln Vivo |
Not applicable to the compound itself. The final nucleoside product (fluorouridine) has anticancer activity. This compound is used in biochemical assays to produce nucleoside monophosphates from nucleobases, enabling studies of pyrimidine metabolism and fluoropyrimidine pharmacology.
|
| Enzyme Assay |
Not applicable - The compound is a substrate, not an inhibitor. Uridine phosphorylase activity is measured by incubating the enzyme with ribose-1-phosphate and 5-fluorouracil. The product (fluorouridine) is quantified by HPLC or UV absorbance to assess enzyme kinetics and evaluate potential inhibitors.
|
| Cell Assay |
Cancer cells are treated with 5-fluorouracil in the presence of ribose-1-phosphate to enhance fluorouridine formation. Cell viability is measured by MTT assay. Nucleotide pool analysis by HPLC can determine the intracellular conversion of 5-FU to active metabolites.
|
| Animal Protocol |
No direct in vivo studies for this compound. However, ribose-1-phosphate is a raw material used in ex vivo or in situ enzymatic assays to produce nucleosides from 5-fluorouracil (FUra) in studies of fluoropyrimidine anticancer drug activation.
|
| ADME/Pharmacokinetics |
As a phosphorylated carbohydrate, the compound has high hydrophilicity and is rapidly cleared from circulation. It is used in vitro or ex vivo, not as a systemic therapeutic. Its stability and PK are not relevant to drug development.
|
| Toxicity/Toxicokinetics |
Ribose-1-phosphate is a natural metabolic intermediate with minimal toxicity. The dicyclohexanamine salt form has acceptable safety for in vitro use. For therapeutic applications of fluorouracil, dose-limiting toxicities include myelosuppression and gastrointestinal mucositis.
|
| References | |
| Additional Infomation |
Ribose-1-phosphate is a research chemical for studying pyrimidine metabolism and fluoropyrimidine pharmacology. It is not a drug and has no clinical approval. It is used primarily in biochemical assays to produce active metabolites for anticancer research.
|
| Molecular Formula |
C17H37N2O8P
|
|---|---|
| Molecular Weight |
428.46
|
| Exact Mass |
428.229
|
| CAS # |
58459-37-3
|
| Related CAS # |
D-Ribofuranose1-dihydrogenphosphate;14075-00-4
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
583.7ºC at 760mmHg
|
| Melting Point |
172-175ºC dec.
|
| Flash Point |
306.8ºC
|
| LogP |
1.49
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3339 mL | 11.6697 mL | 23.3394 mL | |
| 5 mM | 0.4668 mL | 2.3339 mL | 4.6679 mL | |
| 10 mM | 0.2334 mL | 1.1670 mL | 2.3339 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
